# EDGAR Filing Document

**Accession Number:** 0001135951
**File Stem:** 0001575872-25-000498
**Filing Date:** 2025-7
**Character Count:** 10016
**Document Hash:** 359199ad940a0166f6e080067b4c2962
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001575872-25-000498.hdr.sgml**: 20250724

**ACCESSION NUMBER**: 0001575872-25-000498

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 4

**CONFORMED PERIOD OF REPORT**: 20250724

**FILED AS OF DATE**: 20250724

**DATE AS OF CHANGE**: 20250724

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** DR REDDYS LABORATORIES LTD
- **CENTRAL INDEX KEY:** 0001135951
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-15182
- **FILM NUMBER:** 251146470

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 8-2-337, ROAD NO.3 BANJARA HILLS
- **CITY:** HYDERABAD
- **PROVINCE COUNTRY:** K7
- **ZIP:** 500-034
- **BUSINESS PHONE:** 91 40 49002900

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 8-2-337, ROAD NO.3 BANJARA HILLS
- **CITY:** HYDERABAD
- **PROVINCE COUNTRY:** K7
- **ZIP:** 500-034

#### <br>

#### SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

Form 6-K

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16**

#### UNDER THE SECURITIES EXCHANGE ACT OF 1934
**July, 2025**

**Commission File Number 1-15182**

#### DR. REDDY'S LABORATORIES LIMITED
(Translation of registrant's name into English)

**8-2-337, Road No. 3, Banjara Hills**

**Hyderabad, Telangana 500 034, India**

#### +91-40-49002900
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ⌧ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______

**Note:** Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

**Note:** Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ◻ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No ⌧

If "Yes" is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

**EXHIBITS** 

---

| | |
|:---|:---|
| **Exhibit** <br>**Number** | **Description of Exhibits** |
| [99.1](rdy0786_ex99-1.htm) | [Intimation dated July 24, 2025](rdy0786_ex99-1.htm) |

---

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | DR. REDDY'S LABORATORIES LIMITED<br>(Registrant) | DR. REDDY'S LABORATORIES LIMITED<br>(Registrant) |
| Date: July 24, 2025  | By:  | /s/ K Randhir Singh |
|  |  | Name: K Randhir Singh |
|  |  | Title: Company Secretary  |

---

## Exhibit 99.1

**Exhibit 99.1**<br>

---

| | |
|:---|:---|
| ![](rdy0786_ex99-1img01.jpg)<br>| **Dr. Reddy's Laboratories Ltd.**<br>8-2-337, Road No. 3, Banjara Hills<br>Hyderabad – 500 034, Telangana, India <br>CIN: L85195TG1984PLC004507<br>Tel:&nbsp;&nbsp;&nbsp;&nbsp; + 91 40 4900 2900<br>Fax:&nbsp;&nbsp;&nbsp;&nbsp; + 91 40 4900 2999<br>Email: <u>mail@drreddys.com</u><br>Web: <u>www.drreddys.com</u> |

---

July 24, 2025

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited. (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

Dear Sir/Madam,

---

| | |
|:---|:---|
| **Sub:** | **<u>Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015</u>**  |

---

Pursuant to Regulation 30 of SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") and in furtherance to our intimation dated May 09, 2025, wherein we had informed you that the Board of Directors of the Company at their meeting held on the same day, based on the recommendation of Nomination, Governance and Compensation Committee, have approved the re-appointment of Mr. G V Prasad (DIN: 00057433) as a Whole-Time Director designated as Co-Chairman and Managing Director for a period of 5 years with effect from January 30, 2026 to January 29, 2031, subject to approval of shareholders in the ensuing Annual General Meeting of the Company.

This is to inform you that the shareholders of the Company at their 41<sup>st</sup> AGM held today i.e. July 24, 2025 have approved the re-appointment of Mr. G V Prasad (DIN: 00057433) as a Whole-Time Director designated as Co-Chairman and Managing Director with requisite majority.

The details required under Regulation 30 of the SEBI Listing Regulations, read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is enclosed as Annexure-I.

This is for your information and records.

Thanking you.

Yours faithfully,

For **Dr. Reddy's Laboratories Limited**

![](rdy0786_ex99-1img02.jpg)<br>

K Randhir Singh

***Company Secretary, Compliance Officer & Head-CSR***

Encl: as above

![](rdy0786_ex99-1img01.jpg)<br>

**Annexure-I**

**Details under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024**

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Sl.no.** | &nbsp;&nbsp;**Particulars** | &nbsp;&nbsp;**Details** |
| &nbsp;&nbsp;1. | &nbsp;&nbsp;Reason for change viz. appointment, reappointment, resignation, removal, death or otherwise | &nbsp;&nbsp;Re-appointment of Mr. G V Prasad (DIN: 00057433) as a Whole-Time Director designated as Co-Chairman and Managing Director for a period of 5 years with effect from January 30, 2026 to January 29, 2031.<br>|
| &nbsp;&nbsp;2. | &nbsp;&nbsp;Date of appointment / re-appointment / cessation (as applicable) & term of appointment / re-appointment | &nbsp;&nbsp;**Date of re-appointment** – Effective from January 30, 2026<br>**Term** - 5 years commencing from January 30, 2026 to January 29, 2031.<br>|
| &nbsp;&nbsp;3. | &nbsp;&nbsp;Brief profile (in case of appointment) | &nbsp;&nbsp;Mr. G V Prasad is one of our promoters and a member of our Board of Directors. He serves as our Co-Chairman and Managing Director. He has a Bachelor of Engineering degree in Chemical Engineering from Illinois Institute of Technology, Chicago in the United States of America, and an M.S. in Industrial Administration from Purdue University, Indiana in United States of America. Mr. Prasad's emphasis on research, innovation, transparency, business ethics and leaner corporate structures has helped shape Dr. Reddy's into what it is today - an organization of global repute, recognized industry-wide for scientific innovation, progressive people practices and high standards of corporate governance. He is driving the necessary imperatives for our company to engage even more deeply with the human aspects of health. Mr. Prasad focuses on mentoring leaders, driving innovation in science, technology and digitalization while championing the cause of the planet, purpose, and patients. Mr. Prasad also ensures that the company is well-positioned for our future, drawing upon his 36 years plus of leadership experience in the pharmaceutical industry to help our company anticipate trends and envision the future of healthcare.<br>Mr. Prasad is active on the boards of public and private institutions such as the Indian School of Business (ISB) and the International Foundation for Research and Education. Mr. Prasad is also a member of the governing body of Mckinsey Centre for CEO Excellence and Institute of Public Health Sciences Hyderabad Society. Mr. Prasad was listed among the Top 50 CEOs that India ever had by Outlook magazine in 2017 and was recognized as one the top 5 Most Valuable CEOs of India by Business World in 2016. He was also listed in the prestigious 'Medicine Maker 2018 Power List' of most inspirational professionals shaping the future of drug development, and has been named India Business Leader of the year by CNBC Asia, in 2014 & 2015.<br>|
| &nbsp;&nbsp;4. | &nbsp;&nbsp;Disclosure of relationships between directors (in case of appointment of a director) | &nbsp;&nbsp;Mr. G V Prasad is brother-in-law of Mr. K Satish Reddy, Chairman of the Company. |
| &nbsp;&nbsp;5.  | &nbsp;&nbsp;Information as required under BSE circular no. LIST/COMP/14/2018-19 and NSE circular no. NSE/CML/2018/24, dated June 20, 2018 | &nbsp;&nbsp;Mr. G V Prasad is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.  |

---